Atlas Trials

The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma

Clinical trial NCT03022123 · UNKNOWN

Trial details

NCT number
NCT03022123
Sponsor
Hebei Medical University Fourth Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2016-11-01
Primary completion
2017-11-01
Enrollment
270

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.